Pharmaceutical research & development has become laser-focused on the development of specialized drugs, producing some very significant drug innovations over the last several years. The crop of new hepatitis C (HCV) antivirals that first hit the market in 2015 presented hope for converting a chronic disease into one that is instead curable. The same year brought the approval of the United States’ first biosimilar product, which opened the door to greater access and affordability of biologic medications. And this August, the FDA approved the first gene therapy in the U.S., a treatment for select patients with acute lymphoblastic leukemia (ALL), a form of cancer for which few treatment options exist.

SLOW BUT STEADY GROWTH
Drug innovations such as these provide the opportunity to bridge existing gaps in care and reduce the morbidity and mortality associated with chronic and life-threatening conditions. But what role do they currently serve in the care of workers’ compensation populations?

In short: a growing one. Specialty medications have been making their way into workers’ comp claims over the last several years akin to the way a stream is formed. Beginning with a small trickle, and over time carving out a path that gradually becomes both broader and deeper. Broader, as clearer links between certain occupations and illness are established. Deeper, as the cost associated with these medications continues to set new pricing milestones.

Many workers’ comp payers have seen their proportion of specialty drug spend among total pharmacy costs increase by less than 1% over the last year. But individual claims impacted by these medications can become dramatically more expensive when considering these therapies can cost up to 40 times more than traditional medications. Specialty spend across healthcare continues to grow, and continued growth is expected among workers’ compensation claims as well.

THE SPECIALTY DRUG DECISION DILEMMA
Because specialty conditions represent a small minority of workers’ compensation populations (less than 10 percent), drug formularies
Relevance in Workers’ Comp
Needlesticks and sharps injuries in the workplace can expose healthcare workers such as nurses or emergency department workers to infectious diseases, the most common being human immunodeficiency virus (HIV), hepatitis C, and hepatitis B. The Centers for Disease Control and Prevention (CDC) estimate that approximately 385,000 sharps injuries occur among hospital workers each year.

Treatment Decision Points
Quick action needed
For workers exposed to HIV and/or HCV, time is of the essence. When a worker comes into contact with HIV-infected bodily fluids, quick action is needed. While newer agents come at considerable expense, there are important considerations when managing treatment of acute HCV infection. While newer agents come at considerable expense, non-significant clinical benefit over traditional therapies, certain specialties mediations rely heavily on patient adherence. Non-adherence can lead to consequences that include relapse, increased symptoms, increased costs due to absenteeism or hospitalizations, and in cases such as viral infection, resistance to drug therapy.

Following are 6 specialty conditions impacting workers’ compensation claims, and important considerations for managing these populations.

<table>
<thead>
<tr>
<th>Year</th>
<th>Notable Specialty Drugs Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>HCV: Sovaldi® (sofosbuvir) First in a new generation of HCV drugs, offering shorter therapy course and significantly higher “cure” rates vs conventional therapy.</td>
</tr>
<tr>
<td>2014</td>
<td>HCV: Harvoni® (ledipasvir/sofosbuvir) First once-daily tablet regimen for HCV; achieved cure rates 94.99% in clinical trials.</td>
</tr>
<tr>
<td>2015</td>
<td>HCV: Vosevi® (suvorexant/velpatasvir) First drug to treat all six HCV genotypes.</td>
</tr>
<tr>
<td>2016</td>
<td>HCV: Mav Rey® ( FOUR-X® ) First in a new class of oral hepatitis C treatments, with the ability to treat all six HCV genotypes.</td>
</tr>
<tr>
<td>2017</td>
<td>HCV: Thrive® (ronavir/ritonavir) First drug approved to treat HCV genotype 4 without interferon, a drug with severe side effects traditionally used to treat certain viral infections and cancers.</td>
</tr>
</tbody>
</table>

Notable Specialty Drugs Approved Over the Last Few Years

- **HIV & Hepatitis**
  - **HCV**: Sovaldi® (sofosbuvir)
    - First in a new generation of HCV drugs, offering shorter therapy course and significantly higher “cure” rates vs conventional therapy.
  - **Osteoarthrits**: Monovis®
    - Single-injection treatment of osteoarthris of the knee in patients who have failed to respond to conservative therapy.
  - **Psoriatic Arthritis**: Otezla® (apremilast)
    - First-in-class product for treatment of psoriatic arthritis.
  - **Cancer**: Zydelig® (idelalisib)
    - First-in-class drug for multiple B-cell cancers, including relapsed chronic lymphocytic leukemia (CLL).
  - **HIV**: Truvada® (dolutegravir/abacavir/lamivudine)
    - Single-tablet regimen option for HIV-infected patients with impaired kidney function.
  - **HCV**: Harvoni® (ledipasvir/sofosbuvir)
    - First once-daily tablet regimen for HCV; achieved cure rates 94.99% in clinical trials.
  - **Vieka Pak**: An oral and injectable regimen for HCV; improved their likelihood that the patient will progress to chronic HCV. Newer therapies also offer the benefit of not requiring co-treatment with interferon, a drug with severe side effects traditionally used to treat certain viral infections and cancers. However, newer therapies have also increased risk for certain drug interactions, and insight into a patient’s overall drug regimen is critical.

- **Rx Considerations**
  - **HIV**
    - 40+ drugs in development
    - 90+ active trials for HIV
    - 40 drugs approved in U.S. since AIDS first reported
  - **HCV**
    - 8-12 week treatment
    - 90%+ cure rates
    - $65k – $184k per treatment
    - All-Oral regimens
    - 3-4x cost of conventional therapy

- **Gene Therapy**: Kymriah® (tisagenlecleucel)
  - The first gene therapy approved in the United States, indicated for ALL in children up to 25 years of age.

- **Osteoarthritis**: Duralone® (hyaluronic acid) injection
  - For pain in the treatment of pain associated with OA of the knee.

- **Zirelta® (triamcinolone acetonide extended-release injectable suspension)**
  - First-in-class intra-articular injection for osteoarthritis knee pain.
Adherence

2

TRANSLANT

Relevance in Workers’ Comp

Injured workers undergoing transplant due to organ injury will require long-term treatment with immunosuppressive agents, and adherence is essential.

Treatment Decision Points

While generic immunosuppressive options exist, specialty brands can cost upwards of $5,000 per script. Additionally, nonadherence to immunosuppressive therapy can cause the body to reject the transplanted organ, leading to a potential need for re-transplantation, an increase in healthcare costs, with a higher risk of death. Thus, there are benefits to dispensing these medications through a specialty pharmacy program that incorporates clinical management focused on improved adherence, patient education, and counseling services.

Rx Considerations

Kidney transplant ~$260K
Heart & Lung transplant >$1.2M
Limited pipeline Adherence critical

3

PULMONARY FIBROSIS

Relevance in Workers’ Comp

Pulmonary fibrosis is a disease in which deep lung tissue becomes scarred and thickened, impeding the ability to breathe. Occupational/environmental pulmonary fibrosis can occur in occupations including miners, millers, foundry and quarry workers, and sandblasters due to exposure to airborne particles such as asbestos or silica. However, there is also evidence of certain occupational/environmental risk factors for idiopathic pulmonary fibrosis (IPF), an irreversible and fatal form of the disease.

Treatment Decision Points

Treatment of pulmonary fibrosis is dependent on the severity of disease, which is highly variable. For severe and progressive cases, it is important to realize there currently is no cure, and that even the newer therapies can only slow the disease.

Rx Considerations

No current cure for IPF
No FDA-approved Rx before 2014
New “first-in-class” therapies slow disease

4

CARDIOVASCULAR CONDITIONS

Relevance in Workers’ Comp

Emergency responders are at higher risk for cardiovascular (CV) conditions such as hypertension and high cholesterol because of factors that include disruptions to the metabolic syndrome due to shift work and abnormal sleep patterns, noise exposure, occupational stress, and irregular physical exertion. Approximately 3 of 4 emergency responders are hypertensive or pre-hypertensive, and cardiovascular disease events account for 45% and 22% of on-duty deaths among firefighters and police, respectively.

Treatment Decision Points

There is a heavy nonpharmacological aspect to the management of CV conditions in emergency responders. However, pharmacological management must also be considered. There are many traditional, cost-effective medications available to manage hypertension and cholesterol. Specialty PCSK9 inhibitors are not a first-line treatment for cholesterol management. It is also important to consider whether the side effects of any medications prescribed to emergency responders could present occupational safety concerns (e.g., dizziness, somnolence).

Rx Considerations

2015 annual PCSK9 inhibitor cost $14K
2/3 of adults with high cholesterol are not controlled
>$300B direct + indirect cost of CVD/stroke

5

INFLAMMATORY CONDITIONS

Relevance in Workers’ Comp

The prescribing of medications for certain inflammatory conditions in workers’ compensation often enters a gray area. Osteoarthritis (OA) is a common form of arthritis that can be caused by multiple factors, which may include occupations such as mining, construction, agriculture, and sectors of the service industry, due to the physical demands of these jobs. Rheumatoid arthritis (RA), however, is an autoimmune disease that is not considered to be directly work-related. Yet both OA and RA medications are prescribed under workers’ compensation claims.

Treatment Decision Points

Specially drug trends for OA include viscosupplementation, which is the injection of hyaluronic acid (HA) products for treatment of OA in the knee. Market share of these products continues to increase, with the most recent addition of Durolane®, an HA injection approved in September 2017. Specialty RA trends center around biologic disease-modifying antirheumatic drugs (DMARDs) to suppress the body’s immune system. A common example is Humira® (adalimumab), which is currently the #1 therapy in the United States based on spend.

It is important to understand that these therapies, especially OA medications, may be prescribed off-label in workers’ compensation, and not necessarily in the context of OA – a determination that may be extremely difficult when diagnosis is unclear or inaccessible to the workers’ compensation claims professional.

Rx Trends

12 HA injectables on market
~$600-1400+ per HA script (e.g., Synvisc, Orthovisc)
Biologic DMARDs (e.g., Remicade) $2K+ per month

6

CANCERS

Relevance in Workers’ Comp

Occupational cancers can occur due to exposure to cancer-causing agents in the workplace environment, and it is estimated that 4% of all U.S. cancer cases are caused by occupational exposure. The CDC estimates that approximately 46,000 – 92,000 new U.S. cancer cases in 2012 were attributable to occupational exposure. Examples of work-related cancers are lung cancer and mesothelioma related to asbestos exposure, multiple myeloma, which can occur in workers exposed to radiation or petroleum, and non-Hodgkin lymphoma, which has been linked to pesticides in the agricultural industry.
Treatment Decision Points
Cancer is a variable and complex area of medicine for which there is no one-size-fits-all approach. Determining work-related causality is often not black-and-white due to factors such as complexity of disease, disease latency, and individual patient factors. Treatment and duration of therapy are equally as complex based on appropriate agent selection and the variable types and stages of cancer. Because of these complexities, treatment guidelines allow oncologists to tailor treatment appropriately for individual patient circumstances, and off-label prescribing can be a common practice in this therapeutic area. In addition to the primary cancer therapies, adjuvant therapy and its cost must also be considered, as patients will also receive treatments that could include white blood cell boosters and bone marrow stimulants to help offset the adverse effects of chemotherapeutic agents.

Rx Considerations

- $30K approx. cost of 8 weeks’ chemotherapy
- 37 new products launched from 2011-2015

WHAT’S NEXT?

Pain Management: The New Specialty?
Since the introduction of morphine for the medical treatment of pain a century ago, there has been a dearth in drug innovation related to pain management. Fast-forward a couple of years, and pain medications may very well be at the top of this specialty trends list.

With opioids falling out of favor, researchers are exploring alternative, non-opioid pathways to address pain. Most notably, in August 2017, the U.S. Food and Drug Administration (FDA) fast-tracked tanezumab, an investigational, non-opioid biologic for the treatment of osteoarthritis and chronic low back pain. And there is a rich pipeline of other non-opioid products in development (see New Pathways in Pain Management: Novel Non-Opioid Medications on page 12).

While non-opioid alternatives could fill an important gap in chronic pain management, the introduction of specialty medications in this area of healthcare would have an enormous financial impact for treatment decision points.

EVIDENCE-BASED TREATMENT + PRESCRIBER COLLABORATION + PATIENT ADHERENCE

WEIGHING SPECIALTY
Potential positive and negative attributes of specialty medications

+ POTENTIAL BENEFITS
Improved clinical/health outcomes
Better quality of life
Reduced long-term & overall medical costs
Reduced morbidity/mortality
Improved side-effect profiles

- POTENTIAL CONCERNS
Limited clinical experience
Significantly higher drug cost
May only be appropriate in select patients
Adherence management is critical
Unfamiliarity with novel products may lead to inappropriate prescribing

A SNAPSHOT OF SPECIALTY DRUGS IN WORKERS’ COMP

THERAPEUTIC AREA | EXAMPLES IN WORKERS’ COMP | CONSIDERATIONS
--- | --- | ---
HIV & HCV | Truvada®, Isentress®, Kaletra® (lopinavir/ritonavir) | Fast action is critical
| | Ofev® (nintedanib) | Early prophylactic treatment is needed to prevent infection
| | Truvada® (emtricitabine/tenofovir) | HIV/HCV coinfection are a concern

TRANSPLANT | Envarsus®, Prograf® (tacrolimus) | Patient adherence to immunotherapy necessary to avoid increased medical costs over long term
| | CellCept®, Myfortic® (mycophenolic acid) | Generic options exist
| | Rapamune® (sirolimus) | No current cure for idiopathic pulmonary fibrosis

PULMONARY FIBROSIS | Ofev® (nintedanib) | Existing therapies slow disease

CARDIOVASCULAR | Repatha®, Praluent® (alirocumab) | Hypertension and deaths related to cardiovascular events are common among emergency responders
| | | | Many traditional, cost-effective medications available to manage hypertension and cholesterol
| | | | For cholesterol, PCSK9 inhibitors are not first-line treatment

OSTEOARTHRITIS | Simvast-One®, Euflexxa® | Costly hyaluronic acid (HAA) injections often used off-label to treat non-OA pain
| | Orthovisc® | Conservative OA therapy includes oral acetylsalicylic acid or NSAIDs, over-the-counter topical analgesics, or less costly steroidal injections
| | Gal-One® | RA is not work-related, though work functions may exacerbate conditions
| | MovaXisc® Prolia® | IFRA therapy is prescribed, traditional, non-biologic options exist
| | Supartz FX | Adjuvant therapy (white blood cell boosters, bone marrow stimulants) must also be considered

RHEUMATOID ARTHRITIS | Humira® (adalimumab) | Cancer is highly variable and complex
| | Enbrel® | (etanercept) | Off-label prescribing may occur
| | Otezla® (apremilast) | Adjuvant therapy (white blood cell boosters, bone marrow stimulants) must also be considered

CANCERS | Bosulif® (bosutinib) | |
| | Zydelig® (idelalisib) | |
| | Ninlaro® (vismodegib) | |

WEIGHING SPECIALTY
Potential positive and negative attributes of specialty medications